Mitigation of therapeutic anti‐CD38 antibody interference with fab fragments: How well does it perform?
Transfusion · 2023-04 · 63 (4) · 808-816
DOI: 10.1111/trf.17253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, online erschienen am 27.01.2023. Verfasst von Cora P Habicht und 5 weiteren Autor:innen. Beteiligte Einrichtung: Imusyn GmbH & Co. KG, Hanover, Germany. Hauptthemen laut MEDLINE: Blood Transfusion, Multiple Myeloma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Administration of anti‐CD38 antibodies is a state‐of‐the‐art therapy for patients diagnosed with multiple myeloma (MM). However, this treatment frequently leads to pan‐agglutination of red blood cells (RBCs) in patients' serological testing making accurate blood typing and timely transfusion of compatible blood a challenging effort. The antigen masking indirect antiglobulin test (AMIAT) is an approach to address this diagnostic challenge. Study Design and Methods A new reagent, called DaraEx plus , uses anti‐CD38 Fab fragments to mitigate the anti‐CD38 antibody interference in serological assays by masking CD38 on the cell surface. Its performance is extensively examined with commercial sera as well as with patient samples, and compared to the current standard method using dithiothreitol (DTT), which denatures the CD38 antigens on test panel erythrocytes.
Results
In the Bio‐Rad ID System, DaraEx plus effectively mitigated the interference caused by anti‐CD38 antibodies in 86% of patient samples tested while DTT was successful in only 68%. Moreover, there was no negative influence on DTT‐sensitive blood group systems such as KEL upon DaraEx plus treatment. The agglutination reactions of all tested anti‐CD38 antibodies (Daratumumab, Felzartamab, and Isatuximab) were inhibited by DaraEx plus . The treatment was successful only if DaraEx plus was added to the test cells before the sample. Some of the other gel card systems tested showed background reactions with DaraEx plus ‐treated cells.
Conclusion
DaraEx plus treatment is straightforward and quick to perform. In the Bio‐Rad ID System, it is superior to DTT treatment in the prevention of anti‐CD38 antibody interference.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imusyn GmbH & Co. KG, Hanover, Germany.
- Hannover Medical School, Institute of Transfusion Medicine and Transplant Engineering, Hanover, Germany.
ORCID-Profile: Stephan Immenschuh, Clemens Schneeweiss
Zitieren
APA
Habicht, C. P., Ridders, M., Grueger, D., Adolph, S., Immenschuh, S., & Schneeweiss, C. (2023). Mitigation of therapeutic anti‐CD38 antibody interference with fab fragments: How well does it perform?. Transfusion, 63(4), 808-816. https://doi.org/10.1111/trf.17253
Vancouver
Habicht CP, Ridders M, Grueger D, Adolph S, Immenschuh S, Schneeweiss C. Mitigation of therapeutic anti‐CD38 antibody interference with fab fragments: How well does it perform?. Transfusion. 2023;63(4):808-816. doi:10.1111/trf.17253
BibTeX
@article{Habicht2023,
author = {Habicht, Cora P and Ridders, Michael and Grueger, Daniela and Adolph, Svenja and Immenschuh, Stephan and Schneeweiss, Clemens},
title = {Mitigation of therapeutic anti‐CD38 antibody interference with fab fragments: How well does it perform?},
journal = {Transfusion},
year = {2023},
volume = {63},
number = {4},
pages = {808--816},
doi = {10.1111/trf.17253}
}
EUVIMED